33469-36-2

Basic information

• Product Name: 2-Phenyl-4-(trifluoromethyl)-1H-imidazole
• Synonyms: 2-phenyl-4-(trifluoromethyl)-1H-imidazole;2-Phenyl-5-(trifluoroMethyl)-1H-iMidazole;2-Phenyl-4-trifluoromethyl-1,6-dihydro-pyrimidine
• CAS NO: 33469-36-2
• Molecular Formula: C₁₀H₇F₃N₂
• Molecular Weight: 212.17
• Product Categories: Heterocycle
• Mol File: 33469-36-2.mol
• Article Data: 15

Chemical Properties

• Melting Point: 212-213 °C
• Boiling Point: 336.8 °C at 760 mmHg
• Flash Point: 157.5 °C
• Appearance: /
• Density: 1.327
• Vapor Pressure: 0.000214mmHg at 25°C
• Refractive Index: 1.517
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-Phenyl-4-(trifluoromethyl)-1H-imidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Phenyl-4-(trifluoromethyl)-1H-imidazole(33469-36-2)
• EPA Substance Registry System: 2-Phenyl-4-(trifluoromethyl)-1H-imidazole(33469-36-2)

Safety Data

• Hazardous Substances Data: 33469-36-2(Hazardous Substances Data)

Usage

General Description

2-Phenyl-4-(trifluoromethyl)-1H-imidazole is a chemical compound comprised of a phenyl group, a trifluoromethyl group, and an imidazole ring. It is a member of the imidazole class of compounds, which are characterized by a five-membered ring containing two nitrogen atoms. This particular molecule is notable for its trifluoromethyl group, which consists of three fluorine atoms bonded to a single carbon atom. The compound has potential applications in pharmaceuticals and agrochemicals due to its unique structure and potential biological activity. Research on the properties and uses of 2-Phenyl-4-(trifluoromethyl)-1H-imidazole is ongoing in the scientific community.

InChI:InChI=1/C10H7F3N2/c11-10(12,13)8-6-14-9(15-8)7-4-2-1-3-5-7/h1-6H,(H,14,15)

Upstream product

• 670-96-2 2-Phenylimidazole 
• 2926-30-9 sodium triflate 
• 100-52-7 benzaldehyde 
• 431-67-4 1,1-dibromo-3,3,3-trifluoroacetone 
• 111269-38-6 1,1,1-trifluoro-3-(dimethylhydrazono)-2-propanone 
• 2314-97-8 iodotrifluoromethane 
• 725-39-3 N-(3,3,3-trifluoro-2,2-dihydroxypropyl)benzamide 
• 495-69-2 Hippuric Acid 
• 106942-35-2 2-phenyl-4-(2,2,2-trifluoroacetyl)-4H-oxazol-5-one 

Downstream Products

• 77498-98-7 2-phenyl-3H-imidazole-4-carboxylic acid 
• 77498-98-7 2-phenyl-1H-imidazole-4-carboxylic acid 
• 1221277-42-4 (2-phenyl-1H-imidazol-4-yl)(piperidin-1-yl)methanone 
• 1221277-43-5 morpholino(2-phenyl-1H-imidazol-4-yl)methanone 
• 1221277-44-6 N-methyl-N,2-diphenyl-1H-imidazole-4-carboxamide 
• 1221277-45-7 N-(4-methoxyphenyl)-N-methyl-2-phenyl-1H-imidazole-4-carboxamide 
• 787563-21-7 2-phenyl-1-(pyridin-4-yl)-1H-imidazole-4-carboxylic acid 
• 787563-23-9 2-phenyl-1-(4-pyridyl)-1H-imidazole-4-carboxylic acid ethyl ester 
• 32683-00-4 ethyl 2-phenylimidazole-4-carboxylate 
• 1299491-22-7 N-(tert-butoxycarbonyl)-4-trifluoromethyl-2-phenylimidazole 

Relevant articles and documents

BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF

The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as α-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).

PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF

The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as a-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).

Direct trifluoromethylation of imidazoheterocycles in a recyclable medium at room temperature

Regioselective C-H trifluoromethylation of imidazoheterocycles with Langlois' reagent in a recyclable mixed medium of 1-butyl-3-methylimidazoliumtetrafluoroborate ([Bmim]BF4) and water at room temperature has been developed. In the presence of